BioNTech To Supply 100M Coronavirus Vaccine Doses To Chinese Partner Fosun Pharma
Financial Times: BioNTech set to become first foreign jab to enter China market
“BioNTech will supply 100m doses of its coronavirus vaccine to Chinese partner Fosun Pharma for use in mainland China next year in the country’s first publicly announced order of a foreign jab against the disease…” (Shepherd, 12/16).
Additional coverage of the agreement is available from Bloomberg.
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.